A Study to Evaluate Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes

Overview

About this study

The purpose of this study is to test the hypothesis that lower ACT target ranges, as compared to higher target ranges, are associated with reduced rates of bleeding. 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria: 

  • Adults, age >18 years old.
  • Adult patients referred for coronary angiography with possible coronary revascularization or adjunctive invasive diagnostic testing (IVUS/OCT, FFR, or iFR).

Exclusion Criteria: 

  • Receipt of LMWH at treatment dose (not DVT prophylaxis dose) within 6 hours of coronary angiography.
  • Prior GP IIb/IIIa use within the previous 72 hours.
  • Use of warfarin (vitamin K antagonist) or direct oral anticoagulant.
  • Patients on LMWH bridging strategy.
  • PCI within prior 30 days. 
  • Planned use of bivalirudin as the procedural anticoagulant.
  • Rotational atherectomy. 
  • Excimer laser coronary angioplasty.
  • Chronic total occlusions. 
  • Patients with active bleeding disorders or bleeding diathesis.
  • Patients with ST-segment elevation myocardial infarction.
  • Patient with clinical evidence of cardiogenic shock (defined as SBP<90 mmHg for ≥30 min OR support to maintain SBP ≥90 mmHg AND evidence of end-organ hypoperfusion (urine output <30 mL/h or cool extremities).
  • Chronic kidney disease stage 4/5 (GFR 30 mL/min).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Shahyar Gharacholou, M.D.

Open for enrollment

Contact information:

Inna Abrea

127or7833855

Abrea.Inna@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Shahyar Gharacholou, M.D.

Contact us for the latest status

Contact information:

Shahyar Gharacholou M.D.

7837278

Gharacholou.Shahyar@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20453734

Mayo Clinic Footer